In Lysosomal acid lipase deficiency (LIPA, OMIM 278000), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: supply). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.
The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.5269, γ 1.4518, spinodal 0.6733). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.
The emergence switch
The switch for Lysosomal acid lipase deficiency is an R19 double-well emerged from the real proximal-promoter DNA of LIPA. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.
emergent axis
↓ DOWN [F]
healthy branch
ON
lesion
LOF_null
γ (stiffness)
1.4518
barrier
0.5269
spinodal
0.6733
s_on / s_off
1.2049 / -1.2049
fragility
0.33
corrective polarity
supply
forced direction
raise s toward ON branch
Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically harder (barrier 0.5269 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.
The derived corrective lever
The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).
Mechanism. supply / restore the positive drive (replace-or-agonise the missing competence)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If supplying/agonising LIPA (raising the switch drive) does NOT move the DOWN [F] switch toward the healthy branch in a LIPA-deficient model, the h-restore(supply) lever is refuted for this axis.
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual LIPA allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.
Agents mapped onto the lever
✓ Agreement with established practice. The corrective direction derived here (raise s toward ON branch) independently matches an agent already in clinical use for this disease: enzyme replacement (sebelipase alfa). The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)
dir.
status
phase
map
enzyme replacement (sebelipase alfa)
Burton 2015 NEJM 373:1010 (ARISE, sebelipase alfa in LAL deficiency); sebelipase alfa (Kanuma) FDA / EMA 2015
increase
approved
4
✓ in use
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Direction-only candidate leads (corpus join)
Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.
Mechanism. Recombinant human lysosomal acid lipase delivered as enzyme replacement, supplying the hydrolytic competence that the deficient LIPA gene product cannot provide, so accumulated lysosomal cholesteryl esters and triglycerides are cleared. Direction: increase / supply the missing enzymatic competence. Allele scope: agnostic -- the replacement enzyme bypasses the LIPA lesion and does not require residual activity. Gene-specific to LIPA (mapped to lysosomal acid lipase deficiency). An expensive biologic -- the cost barrier remains -- but it is the approved disease-modifying therapy the supply direction recovers.
✓ This is a rediscovery. Sebelipase alfa (recombinant LAL enzyme replacement) is approved for lysosomal acid lipase deficiency; recovered by the direction logic. Expensive biologic -- cost barrier remains.
Safety (qualitative; no magnitude). post-marketing safety profile on record (approved for lysosomal acid lipase deficiency; infusion-reaction signal noted on label; qualitative; no magnitude)
Falsifier. If sebelipase alfa (a gene-specific supply/increase agent) does NOT move the DOWN [F] switch toward the healthy branch in a LIPA-deficient model, the h-restore(supply) direction is refuted for sebelipase alfa here.
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Evidence & provenance
What is reproduced vs. cited for this page.
element
grade
basis
R19 switch & cusp geometry (this page)
[V] verified
emerged from measured promoter γ of LIPA; deterministic, 2×sha256 identical
corrective direction
[F] forced
forced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads
[O] open
direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude
Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).